| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-144SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF2519-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-145SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-59724SS | |||
| Azide and BSA Free | NBP2-80643 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB2519-SP | |||
![<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: CD36 Antibody [NB400-144] - Total protein from Human Skin and Adipose tissue, Mouse Adipose and Rat Adipose tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-CD36 in 5% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Western-Blot-NB400-144-img0009.jpg)
![Immunohistochemistry-Paraffin: CD36 Antibody [NB400-144] - Staining of CD36 in human adipocytes.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Immunohistochemistry-Paraffin-NB400-144-img0005.jpg)
![Western Blot: CD36 Antibody [NB400-144] - Mouse primary muscle cell lysate. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Western-Blot-NB400-144-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: CD36 Antibody [NB400-144] - Bone marrrow derived mouse macrophages stained with CD36 antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Immunocytochemistry-Immunofluorescence-NB400-144-img0017.jpg)
![Western Blot: CD36 Antibody [NB400-144] - Detection of CD36 in human adipocyte extract (30 ug). Lane 1: 0.5 ug/ml NB 400-144; lane 2: 2 ug/ml NB 400-144. ECL: 3 second exposure.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-Western-Blot-NB400-144-img0004.jpg)
![Western Blot: Rabbit Polyclonal CD36 Antibody [NB400-144] - The western blot was conducted on avian (passerine) skeletal muscle tissue homogenate. 6ug of total protein was loaded and GAPDH was probed to ensure total protein loads were similar across samples. Rabbit polyclonal CD36 antibody (NB400-144) was used at 1:5000 dilution (diluted in 5% milk). CD36 and GAPDH were probed sequentially - not multiplexed. CD36 produced a band above 40kDa and GAPDH at 36kDa. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb400-144_rabbit-polyclonal-cd36-antibody-western-blot-13202413439..png)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-144] - Timp4-deficiency results in defective lipid digestion & absorption. Fecal triglyceride (TG) content (Ai) in chow- or HFD-fed WT & Timp4−/− mice. Fecal lipid analysis by thin layer chromatography in chow-fed (Aii) & HFD-fed (iii) WT & Timp4−/− mice. (B) Immunostaining for CD36 in small intestine (proximal region) of chow-fed & HFD-fed WT & Timp4−/− mice. Western blot (C) & mRNA (D) levels for CD36 in enterocyte fraction of chow-fed & HFD-fed WT & Timp4−/− mice (collected from the proximal small intestine). (E) Triglyceride levels in enterocytes collected from the proximal small intestine. Averaged data are presented as mean ± S.E.M & analyzed by ANOVA. * indicates significance (p < 0.05). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05951-4), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-310202415293346.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - Timp4-deficiency results in defective lipid digestion & absorption. Fecal triglyceride (TG) content (Ai) in chow- or HFD-fed WT & Timp4−/− mice. Fecal lipid analysis by thin layer chromatography in chow-fed (Aii) & HFD-fed (iii) WT & Timp4−/− mice. (B) Immunostaining for CD36 in small intestine (proximal region) of chow-fed & HFD-fed WT & Timp4−/− mice. Western blot (C) & mRNA (D) levels for CD36 in enterocyte fraction of chow-fed & HFD-fed WT & Timp4−/− mice (collected from the proximal small intestine). (E) Triglyceride levels in enterocytes collected from the proximal small intestine. Averaged data are presented as mean ± S.E.M & analyzed by ANOVA. * indicates significance (p < 0.05). Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05951-4), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-31020241535667.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - MiR-29a inhibits the expression of fatty acid translocase CD36 by targeting 3’ untranslated region (UTR). (A) qPCR analysis of Cd36 in live tissue. (B) Representative immunoblotting bands & densitometric results of CD36 in liver tissue. (C) qPCR analysis of cd36 expression of HepG2 cells in vitro after 48h transfection of scramble sequence or miR-29a-mimic. Data obtained from six independent experiments. (D) Upper panel, sequence information, & mutual pairing status of CD36-3’UTR, mmu-miR29a, & CD36-3’UTR Mut. Note that red characters represent mismatching sites. HepG2 was first transfected with CD36-3’UTR or CD36-3’UTR mutant luciferase reporter construct then treated with control medium (ctrl), miRNA-scramble, or miR-29a mimic, & finally lysed to detect the luciferase signal. Data are expressed as mean ± SE. * p < 0.05, ** p < 0.01, & *** p < 0.001 between the indicated groups. WT, wild type mice. HFD, high-fat diet. miR-29a, mice harboring overexpression of miR-29a. mmu-miR29a, mouse-origin miR-29a. ctrl, control. Mut, mutant. UTR, untranslated region. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31652636), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-310202416173544.jpg)
![Immunohistochemistry: CD36 Antibody - BSA Free [NB400-144] - Integrin beta 3 modulates SMC transdifferentiation. a–c Mice were fed a HFD for 6 or 16 weeks as indicated, & then transverse aortic root sections were stained. In a, b sections from ApoE(−/−), SMMHC-CreERT2, ROSA26R(mTmG/+) mice were stained for SMA, GFP (fate marker), nuclei (DAPI), & either integrin beta 3 (a) or CD36 (b). Dashed yellow lines separate cap from core (a, b) & core from media (b). n = 5. In c sections from ApoE(−/−) mice that were also wild type or null for Itgb3 were stained for SMMHC, CD68, & nuclei (DAPI). n = 3. Boxed regions (a, c) are shown as close-ups on right; in c CD68+SMMHC+ cells in the media (arrowheads) & plaque (arrows) of the Itgb3 null atherosclerotic aorta are indicated. Med, tunica media; Lu, lumen; Pl, plaque. Scale bars, 25 μm. d–h Aortic SMCs were isolated from ApoE(−/−) mice & then subjected to siRNA-mediated knockdown with si-Itgb3 vs. scrambled (Scr; d–f) or with si-Itgb3, si-Tlr4 vs. si-Itgb3 (g, h). Levels of indicated transcripts from qRT-PCR are relative to Gapdh & normalized to either Scr in d, f or to si-Itgb3 in g, h. For d, g, n = 4–5 in duplicate. In e silenced SMCs were cultured with DiI-conjugated ox-LDL for 10 h & stained with DAPI; n = 5. In f, h silenced SMCs were exposed to soluble cholesterol:methyl-beta -cyclodextrin complexes for 3 days, & then mRNA levels were assessed; n = 4–7 in duplicate. *, **, ***, ^, **** vs. control (Scr in d, f & si-Itgb3 in g, h), p < 0.05, p < 0.01, p < 0.005, p < 0.001, & p < 0.0005, respectively. NS, not significant. Student’s t-test was used, & error bars represent standard deviations. i Schematic of the effect of beta 3 reduction via TLR4 & CD36 in SMCs on transdifferentiation Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-04447-7), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-310202416161810.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - The increase in CD36 levels caused by lipids in Sirt3-deficient hepatocytes is mediated by Nrf2. VLDLR mRNA abundance (a) & protein levels of VLDLR & NQO1, an Nrf-2-target gene, (b) were assessed in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. c, fatty acid uptake in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h was measured by the uptake of BODIPY-C16. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. mRNA abundance (d) & protein levels of VLDLR (e) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) for 24 h. Protein levels of CD36 (f), NQO1 (g) & PPAR gamma (h) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) or the Nrf2 inhibitor ML385 (10 μM) for 24 h. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p < 0.05 vs. SIRT3 siRNA cells. d, p < 0.05 vs. CT siRNA cells incubated with palmitate & ML385 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32912335), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-31020241616372.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-144] - The increase in CD36 levels caused by lipids in Sirt3-deficient hepatocytes is mediated by Nrf2. VLDLR mRNA abundance (a) & protein levels of VLDLR & NQO1, an Nrf-2-target gene, (b) were assessed in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. c, fatty acid uptake in Huh-7 cells incubated with fatty acid free-BSA or BSA-palmitate (0.3 mM) & exposed to either vehicle or the Sirt3 inhibitor AAPBO (100 μM) for 16 h was measured by the uptake of BODIPY-C16. a, p < 0.05 vs. CT. b, p < 0.05 vs. CT cells incubated with palmitate. c, p < 0.05 vs. CT cells treated with AAPBO. mRNA abundance (d) & protein levels of VLDLR (e) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) for 24 h. Protein levels of CD36 (f), NQO1 (g) & PPAR gamma (h) in Huh-7 cells transfected with control (CT) or SIRT3 siRNA & incubated in the presence or absence 0.3 mM palmitate (Pal) or the Nrf2 inhibitor ML385 (10 μM) for 24 h. a, p < 0.05 vs. CT siRNA cells. b, p < 0.05 vs. CT siRNA cells incubated with palmitate. c, p < 0.05 vs. SIRT3 siRNA cells. d, p < 0.05 vs. CT siRNA cells incubated with palmitate & ML385 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32912335), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-144_rabbit-polyclonal-cd36-antibody-31020241617350.jpg)
![Simple Western: CD36 Antibody [NB400-145] - Image shows a specific band for CD36 in human adipose lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD36-Antibody-Simple-Western-NB400-145-img0007.jpg)
![Western Blot: CD36 Antibody [NB400-145] - Detection of CD36 in human adipocyte extract (30 ug). Lane 1: 0.5 ug/ml NB 400-145; lane 2: 2 ug/ml NB 400-145. ECL: 3 second exposure.](http://images.novusbio.com/fullsize/CD36-Antibody-Western-Blot-NB400-145-img0006.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241618930.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241616182.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241618949.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-310202416173513.jpg)
![Western Blot: CD36 Antibody (D-2712) [NB110-59724] - Detection of CD36 in mouse adipose lysate.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-D-2712-Western-Blot-NB110-59724-img0007.jpg "Western Blot: CD36 Antibody (D-2712) [NB110-59724] - Detection of CD36 in mouse adipose lysate.")
![Immunohistochemistry: CD36 Antibody (D-2712) [NB110-59724] - Staining of CD36 in mouse liver.](http://images.novusbio.com/fullsize/CD36-SR-B3-Antibody-D-2712-Immunohistochemistry-NB110-59724-img0006.jpg)
